Enovis (NYSE:ENOV) Stock Price Up 13.7% on Strong Earnings

Shares of Enovis Corporation (NYSE:ENOV) rose 13.7% on Thursday following a better than expected earnings announcement. The stock traded as high as $25.31 and last traded at $25.38. Approximately 254,281 shares traded hands during trading, a decline of 77% from the average daily volume of 1,090,022 shares. The stock had previously closed at $22.32.

The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The company had revenue of $575.76 million during the quarter, compared to analyst estimates of $584.30 million. Enovis had a positive return on equity of 7.79% and a negative net margin of 61.22%.The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS.

Analysts Set New Price Targets

Several research firms have recently commented on ENOV. UBS Group reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Enovis in a report on Monday, January 5th. Canaccord Genuity Group cut their price target on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Wells Fargo & Company lifted their price objective on Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. BTIG Research started coverage on Enovis in a research note on Tuesday, January 6th. They issued a “buy” rating and a $41.00 target price on the stock. Finally, Evercore reiterated an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Insider Transactions at Enovis

In other Enovis news, EVP Daniel A. Pryor sold 999 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Enovis

A number of large investors have recently added to or reduced their stakes in ENOV. Arax Advisory Partners purchased a new stake in shares of Enovis during the fourth quarter worth about $29,000. Farther Finance Advisors LLC increased its stake in Enovis by 42.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after buying an additional 367 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new position in shares of Enovis in the second quarter valued at approximately $46,000. Finally, SJS Investment Consulting Inc. boosted its stake in shares of Enovis by 30,340.0% in the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after acquiring an additional 1,517 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Price Performance

The company has a 50-day moving average of $24.34 and a 200 day moving average of $28.23. The company has a quick ratio of 1.16, a current ratio of 2.22 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $1.43 billion, a PE ratio of -1.06 and a beta of 1.52.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.